AGIO Agios Pharm

$40.89

*Only the 1D chart reflects 15-min delayed quotes during market hours. Other timeframes update after market close.

Reporting for fiscal period ending —
Expected on —
Report Time: Unknown Release Time
The Whisper Number
—
Consensus Estimate: —
Revenue Estimate: —

Latest Earnings Insight

Updated On 10/6/2025

About Agios Pharm

Agios Pharmaceuticals, Inc., a biopharmaceutical company, is dedicated to drug discovery and development in the field of cellular metabolism and adjacent areas of biology. The company is headquartered in Cambridge, Massachusetts.

Website: https://www.agios.com

Sector
LIFE SCIENCES
Industry
PHARMACEUTICAL PREPARATIONS
Exchange
NASDAQ
Country
USA
Currency
USD
Fiscal Year End
December
CIK
1439222
Address
88 SIDNEY STREET, CAMBRIDGE, MA, US
Valuation
Market Cap
$1.58B
P/E Ratio
2.38
PEG Ratio
0.00
Price to Book
1.03
Performance
EPS
$11.64
Dividend Yield
—
Profit Margin
1846.00%
ROE
57.30%
Technicals
50D MA
$31.23
200D MA
$41.04
52W High
$62.58
52W Low
$23.41
Fundamentals
Shares Outstanding
57M
Target Price
$53.32
Beta
0.83

AGIO EPS Estimates vs Actual

● Estimated
● Actual

AGIO News & Sentiment

Sep 24, 2025 • Benzinga NEUTRAL
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Agios Pharmaceuticals, Inc. - AGIO - Agios Pharmaceuticals ( NASDAQ:AGIO )
NEW YORK, Sept. 24, 2025 ( GLOBE NEWSWIRE ) -- Pomerantz LLP is investigating claims on behalf of investors of Agios Pharmaceuticals, Inc. ( "Agios" or the "Company" ) AGIO. Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
Sep 15, 2025 • Benzinga SOMEWHAT-BULLISH
Atavistik Bio Expands Leadership Team with Appointment of Susan Pandya, M.D., as Chief Medical Officer
Dr. Pandya brings 20 years of drug development expertise in precision medicine in both oncology and hematology, with previous senior leadership roles at Servier Pharmaceuticals and Agios Pharmaceuticals
Sep 10, 2025 • Benzinga NEUTRAL
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Agios Pharmaceuticals, Inc. - AGIO - Agios Pharmaceuticals ( NASDAQ:AGIO )
NEW YORK, Sept. 10, 2025 ( GLOBE NEWSWIRE ) -- Pomerantz LLP is investigating claims on behalf of investors of Agios Pharmaceuticals, Inc. ( "Agios" or the "Company" ) AGIO. Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
Sep 05, 2025 • Zacks Commentary NEUTRAL
AGIO Stock Falls as FDA Delays Decision on Pyrukynd for Thalassemia
Agios shares tank as the FDA extends the review period for Pyrukynd in thalassemia by three months, pushing the final ruling to Dec. 7, 2025.
Sep 04, 2025 • Benzinga NEUTRAL
FDA Delays Decision On Agios Pharmaceuticals' Blood Disorder Drug For Expanded Use - Agios Pharmaceuticals ( NASDAQ:AGIO )
FDA extends Pyrukynd supplemental marketing application decision date to December 7, 2025. REMS submission to address liver injury risk triggered a delay. September's volatility catalysts are coming. Find out how to trade new inflation reports and fed signals here → On Thursday, the U.S.
Sep 03, 2025 • Zacks Commentary SOMEWHAT-BULLISH
Why Is Vertex ( VRTX ) Up 6.9% Since Last Earnings Report?
Vertex (VRTX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Sentiment Snapshot

Average Sentiment Score:

0.013
50 articles with scored sentiment

Overall Sentiment:

Neutral

AGIO Reported Earnings

Apr 30, 2025
Mar 31, 2025 (Pre market)
0.21 Surprise
  • Reported EPS: $-1.55
  • Estimate: $-1.76
  • Whisper: —
  • Surprise %: 11.9%
Feb 13, 2025
Dec 31, 2024 (Pre market)
-0.11 Surprise
  • Reported EPS: $-1.74
  • Estimate: $-1.63
  • Whisper: —
  • Surprise %: -6.8%
Oct 31, 2024
Sep 30, 2024 (Pre market)
-3.53 Surprise
  • Reported EPS: $-2.42
  • Estimate: $1.11
  • Whisper: —
  • Surprise %: -318.0%
Aug 01, 2024
Jun 30, 2024 (Pre market)
-0.09 Surprise
  • Reported EPS: $-1.69
  • Estimate: $-1.60
  • Whisper: —
  • Surprise %: -5.6%
May 02, 2024
Mar 31, 2024 (Pre market)
0.2 Surprise
  • Reported EPS: $-1.45
  • Estimate: $-1.65
  • Whisper: —
  • Surprise %: 12.1%
Feb 15, 2024
Dec 31, 2023 (Pre market)
-0.07 Surprise
  • Reported EPS: $-1.72
  • Estimate: $-1.65
  • Whisper: —
  • Surprise %: -4.2%
Nov 02, 2023
Sep 30, 2023 (Pre market)
0.06 Surprise
  • Reported EPS: $-1.64
  • Estimate: $-1.70
  • Whisper: —
  • Surprise %: 3.5%
Aug 03, 2023
Jun 30, 2023 (Pre market)
0.05 Surprise
  • Reported EPS: $-1.51
  • Estimate: $-1.56
  • Whisper: —
  • Surprise %: 3.2%
May 04, 2023
Mar 31, 2023 (Pre market)
0.23 Surprise
  • Reported EPS: $-1.47
  • Estimate: $-1.70
  • Whisper: —
  • Surprise %: 13.5%

Financials